| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Anthony L McCall | |
| David C Lieb | |||
| P2860 | cites work | Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes | Q22250883 |
| Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. The Bypass Angioplasty Revascularization Investigation (BARI) Investigators | Q28281001 | ||
| Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes | Q29547541 | ||
| Effects of intensive glucose lowering in type 2 diabetes | Q29547736 | ||
| 10-year follow-up of intensive glucose control in type 2 diabetes | Q29615973 | ||
| Glucose control and vascular complications in veterans with type 2 diabetes | Q29619213 | ||
| Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial | Q29619886 | ||
| Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy | Q29620534 | ||
| Mechanisms by which diabetes increases cardiovascular disease | Q30441275 | ||
| When is evidence of lack of harm enough? Has the rosiglitazone controversy ended? | Q30449153 | ||
| Rosiglitazone monotherapy is effective in patients with type 2 diabetes | Q32088604 | ||
| The Bypass Angioplasty Revascularization Investigation 2 Diabetes randomized trial of different treatment strategies in type 2 diabetes mellitus with stable ischemic heart disease: impact of treatment strategy on cardiac mortality and [...] | Q33696402 | ||
| A randomized trial of therapies for type 2 diabetes and coronary artery disease | Q33827504 | ||
| The effect of interventions to prevent cardiovascular disease in patients with type 2 diabetes mellitus | Q34469901 | ||
| The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study | Q34623719 | ||
| Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis | Q34634794 | ||
| Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials | Q34686089 | ||
| Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis | Q34686103 | ||
| Pioglitazone and cardiovascular risk. A comprehensive meta-analysis of randomized clinical trials | Q34781949 | ||
| Rationale for and role of thiazolidinediones in type 2 diabetes mellitus | Q34856939 | ||
| Cardiac safety profile of rosiglitazone: a comprehensive meta-analysis of randomized clinical trials. | Q34970508 | ||
| Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial | Q34985342 | ||
| Thiazolidinedione use and bone loss in older diabetic adults | Q35023205 | ||
| Hepatotoxicity of the thiazolidinediones | Q35184558 | ||
| Activation of peroxisome proliferator-activated receptor gamma (PPARgamma) by rosiglitazone suppresses components of the insulin-like growth factor regulatory system in vitro and in vivo | Q35748476 | ||
| Rosiglitazone and pioglitazone utilization from January 2007 through May 2008 associated with five risk-warning events | Q37240896 | ||
| Thiazolidinediones and congestive heart failure: a judicious balance of risks and benefits | Q37454218 | ||
| Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database. | Q37460057 | ||
| Trends in cardiovascular disease risk factors in individuals with and without diabetes mellitus in the Framingham Heart Study | Q37461920 | ||
| A cardiologic approach to non-insulin antidiabetic pharmacotherapy in patients with heart disease. | Q37556648 | ||
| Systematic review: glucose control and cardiovascular disease in type 2 diabetes | Q37557021 | ||
| Is the evidence from clinical trials for cardiovascular risk or harm for glitazones convincing? | Q37606015 | ||
| Use of thiazolidinediones and fracture risk | Q38456774 | ||
| National Cholesterol Education Program and International Diabetes Federation definitions of metabolic syndrome in the prediction of diabetes. Results from the FIrenze-Bagno A Ripoli study | Q39213508 | ||
| Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections | Q39474763 | ||
| Increasing cardiovascular disease burden due to diabetes mellitus: the Framingham Heart Study | Q42165604 | ||
| Thiazolidinediones and fractures in men and women | Q43295115 | ||
| Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation | Q45182791 | ||
| A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia | Q46570674 | ||
| Thiazolidinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption | Q46592677 | ||
| Anti-inflammatory effects of short-term pioglitazone therapy in men with advanced diabetic nephropathy | Q46701051 | ||
| Sulfonylurea drugs increase early mortality in patients with diabetes mellitus after direct angioplasty for acute myocardial infarction. | Q50535464 | ||
| Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group. | Q51552529 | ||
| Effect of various diuretic treatments on rosiglitazone-induced fluid retention. | Q51777309 | ||
| Role of K+ATP channels in coronary vasodilation during exercise | Q72885849 | ||
| Pioglitazone reduces urinary protein and urinary transforming growth factor-beta excretion in patients with type 2 diabetes and overt nephropathy | Q83030080 | ||
| P433 | issue | 2 | |
| P304 | page(s) | 116-123 | |
| P577 | publication date | 2010-04-01 | |
| P1433 | published in | Current diabetes report | Q26841965 |
| P1476 | title | Update on the safety of thiazolidinediones | |
| P478 | volume | 10 |
Search more.